Prelude Therapeutics Inc (PRLD) is a Healthcare · Biotechnology company listed on NASDAQ. Price $4.78 (+4.60%), Market cap $0.34B, 52-week low–high $0.78 ~ $5.52.
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016
Financial statements, price targets, institutional (13F) holdings and related news for Prelude Therapeutics Inc are updated in real time on BlackAll Trade.
Prelude Therapeutics Inc trades at $4.78 (+4.60%). Real-time quotes and charts are available on BlackAll Trade.
Prelude Therapeutics Inc has a market cap of about $0.34B.
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing J